SSA
KRYS icon

Schonfeld Strategic Advisors’s Krystal Biotech KRYS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,624
Closed -$3.36M – 2302
2025
Q1 		$3.36M Buy
18,624
+11,020
+145% +$1.85M 0.02% 689
2024
Q4 		$1.19M Buy
7,604
+1,153
+18% +$205K 0.01% 1040
2024
Q3 		$1.17M Buy
6,451
+581
+10% +$112K 0.01% 1108
2024
Q2 		$1.08M Buy
5,870
+3,729
+174% +$626K 0.01% 1173
2024
Q1 		$381K Sell
2,141
-23,425
-92% -$3.25M ﹤0.01% 1567
2023
Q4 		$3.17M Sell
25,566
-58,069
-69% -$6.44M 0.02% 649
2023
Q3 		$9.7M Buy
83,635
+65,325
+357% +$7.97M 0.08% 359
2023
Q2 		$2.15M Buy
+18,310
New +$1.87M 0.02% 728
2022
Q4 		– Sell
-5,159
Closed -$359K – 2827
2022
Q3 		$359K Buy
+5,159
New +$373K ﹤0.01% 1974

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Schonfeld Strategic Advisors's KRYS Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 18,624 shares — an estimated $3.36M sold.

Schonfeld Strategic Advisors first reported a position in KRYS in Q3 2022 and held it in 9 quarters. The position peaked at $9.7M in Q3 2023. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 18,624 Krystal Biotech shares in Q2 2025, an estimated $3.36M.
  • Schonfeld Strategic Advisors first reported a position in Krystal Biotech in Q3 2022 and held it in 9 quarters.
  • Schonfeld Strategic Advisors's Krystal Biotech position peaked at $9.7M in Q3 2023.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.